期刊
NATURE CANCER
卷 1, 期 7, 页码 672-680出版社
NATURE PORTFOLIO
DOI: 10.1038/s43018-020-0088-5
关键词
-
类别
资金
- University of Lyon, France
- IDEX Lyon mobility fellowship
- US National Institutes of Health [CA109182, CA218024, CA216248, CA196521]
- Jimmy V Foundation
- Falk Medical Research Trust
- HiberCell
- Metavivor
- Fondation de France/Fondation Ramona Ehrman Amador [2014-0047501, 2017-00076282]
- Association Laurette Fugain [ALF2014-03]
- Ligue contre le Cancer
- Association ALTE-SMP
- Institut Convergence PLASCAN
- CLARA mobility fellowship
Disseminated tumor cells (DTCs) are known to enter a state of dormancy that is achieved via growth arrest of DTCs and/or a form of population equilibrium state, strongly influenced by the organ microenvironment. During this time, expansion of residual disseminated cancer is paused and DTCs survive to fuel relapse, sometimes decades later. This notion has opened a new window of opportunity for intervening and preventing relapse. Here we review recent data that have further augmented the understanding of cancer dormancy and discuss how this is leading to new strategies for monitoring and targeting dormant cancer. Aguirre-Ghiso and colleagues discuss the current status of the cancer dormancy field, including challenges and opportunities for monitoring and targeting dormant cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据